# Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients

> **NCT00662831** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 276 (actual)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **DRUG:** Fragmin/ Dalteparin Sodium
- **DRUG:** Placebo for Fragmin/ Dalteparin Sodium

## Key facts

- **NCT ID:** NCT00662831
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662831, "Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00662831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*